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Abstract
In tumour xenograft experiments, treatment regimens are admin-
istered and the tumour volume of each individual is measured repeat-
edly over time. Survival data are recorded due to the death of some
individuals during the observation time period. Also, cure data are
observed due to a portion of individuals who are completely cured
in the experiments. When modelling these data, certain constraints
have to be imposed on the parameters in the models to account for
the intrinsic growth of the tumour in the absence of treatment. Also,
the likely inherent association of longitudinal and survival-cure data
has to be taken into account in order to obtain unbiased estimators of
parameters. In this paper, we propose such models for the joint mod-
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elling of longitudinal and survival-cure data arising in xenograft ex-
periments. Estimators of parameters in the joint models are obtained
using a Markov chain Monte Carlo approach. Real data analysis of
a xenograft experiment is carried out and simulation studies are also
conducted, showing that the proposed joint modelling approach out-
performs the separate modelling methods in the sense of mean squared
errors.
Keywords: Constrained parameters; joint longitudinal and survival-cure model;
Markov chain Monte Carlo; xenograft experiment.
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1 Introduction
In cancer drug development, demonstrating anti-tumor activity in an in vivo
experiment is an important and necessary step to make a promising experi-
mental treatment available to humans. The xenograft model is a commonly
used in vivo model in cancer research, for which severe combined immun-
odeficient (scid) mice are grafted with human cancer cells after which they
receive a treatment and are then followed up. Tan et al. [1] presented a
typical xenograft experiment, where several treatment regimens are adminis-
tered and an outcome variable, tumour volume, is measured at the start of the
treatment and then at regular follow-up times. In the literature, methodol-
ogy has been developed to analyze repeated measurements and survival times
collected from xenograft experiments. For example, Tan et al. [2] developed
a t-test via the EM algorithm and also a Bayesian approach for testing for
differences in effects between two treatment regimens. If no treatment were
given to the tumour-bearing mice, the tumours would keep growing until
the mice died or are sacrificed. Therefore, certain constraints have to be
imposed on the parameters in the model to account for the intrinsic growth
of a tumour in the absence of treatment. Tan et al. [1] considered a class
of regression models for longitudinal outcomes with constrained parameters.
Fang et al. [3] proposed a Bayesian hierarchical model to account for the pa-
rameter constraints. However, these authors ignored the very likely inherent
association between longitudinal responses and survival outcomes for data
coming from the same subject. As a result, such statistical inferences may
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be biased.
Joint models for both longitudinal and survival data have been developed in
recent years and are extensively reviewed by [4]. It is well known nowadays
that analyzing combined longitudinal data and survival data can lead to a
significant improvement in the efficiency of statistical modelling compared
to the separate analyses - see, for example, [5], [6], [7], [8], [9], [10], [11],
[12] and [13]. When there are cured individuals in the survival studies, ei-
ther due to immunes or long-term survivors, joint models for survival and
cured data have been considered by [14], [15], [16] and [17]. Longitudinal
and survival-cure models have been further developed by [18], [19] and [20].
The mixture distribution for the longitudinal model in [18] is very unique
which is not suitable to our study. Yu and his colleagues [19, 20] studied a
prostate cancer data, where longitudinal data have an inherent relationship
with survival outcomes and survival hazard rate are modelled separately for
cured patients and uncured patients. However, these models are not suit-
able for analyzing the tumour data arising in xenograft experiments for the
following reason. This is because these models assume the cure probability
only depends on the baseline covariates. This assumption may not be true
in xenograft experiments because the cure probability of a mouse will clearly
be related not only to the baseline tumor size but also to how fast the tumor
grows or other characteristics of tumor volumes.
In this paper, motivated by an xenograft experiment for mice, we propose new
joint models for longitudinal and survival-cure data by taking into account
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not only the likely inherent association of the different types of data but
also the intrinsic growth of a tumour in the absence of any treatment [21].
The random effects in linear mixed models for longitudinal data, after being
properly scaled, are incorporated into the Cox hazard model for survival
data and the logistic model for cure data, so that the inherent association
between the different types of data can be accounted for. The fixed effects
in the longitudinal linear mixed models, on the other hand, are imposed
constraints in order to account for the intrinsic growth of a tumour in the
absence of treatment. Posterior inferences for the parameters in the models
are obtained by using a Markov chain Monte Carlo (MCMC) method.
The rest of the paper is organized as follows. In Section 2, we define the
joint longitudinal and survival-cure models for the xenograft experimental
data and provide the log-likelihood function for the complete data. In Sec-
tion 3, we specify prior distributions for the parameters and provide model
selection criteria for finding the best model. In Section 4, we use an MCMC
method to generate random samples from the posterior distributions of the
parameters and apply to the real xenograft data analysis involving two new
anticancer agents against rhabdomyosarcomas. In Section 5 we carry out
simulation studies to assess the performance of the proposed approach. Nu-
merical results show that the proposed joint modelling strategy outperforms
the separate modelling methods. Further comments and discussions are given
in Section 6.
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2 Data and Models
2.1 Data set
The xenograft experimental data in [1] and [24] are about two new anticancer
agents: temozolomide (TMZ) and irinotecan (CPT-11). TMZ is a methylat-
ing agent that has been approved for treatment of astrocytoma and is entering
various phases of clinical evaluation against tumours. CPT-11 has demon-
strated a broad activity against both murine and human tumour xenograft
models and clinically significant activity against many types of cancer. A
DNA analysis has formed the biochemical rationale for combining TMZ and
CPT-11. Our primary objective is to analyze the activity of TMZ com-
bined with CPT-11 against one rhabdomyosarcoma (Rh18) xenograft. Mice
from the same strain were used and they are virtually genetically identical.
In total, we have 51 subjects (mice) observed, which are divided into eight
groups for different treatment regimens. Two dose levels were considered
for both anticancer agents; for TMZ the two weekly dose levels considered
are 140mg/kg and 210mg/kg; for CPT-11 the two levels are 2.0mg/kg or
3.05mg/kg. Tumor-bearing mice were treated under certain levels of either
TMZ, CPT-11 or both. Note that the mice were treated on a one-week or
two-week courses per three-week cycle. Table 1 in the Supplementary Web
Materials provides more detailed information.
The tumour volume was measured at the initial time and once a week within
the follow-up period of 12 weeks. Figure 1 shows the change of tumor volume
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(cm3) with time for mice in each of the eight treatment groups.
[Figure 1 about here.]
From Figure 1, it is clear that in the control group (i.e., no treatment) the
tumor volume increases with time, while in other treatment groups the tu-
mor volume may decrease in the beginning and then increase at later times.
Figure 1 displays the longitudinal measurements observed until mice died or
were sacrificed due to the tumour volume quadrupled. Among these 51 mice,
in total 25 mice either died of toxicity or were sacrificed and the remaining
26 mice survived longer than the 12-week observation period. For these sur-
vived ones, their lifetimes cannot be observed but were censored at the end of
12 weeks. On the other hand, 14 mice quickly shrank their tumour volumes
smaller than 0.01cm3, which became too small to be observable by a reading
machine, and had no recurrent growth of tumour in the rest period of the
experiment. For this portion of mice, it is believed that they are very likely
cured already, see [1] for more details. We also note that a few of the mice
had the tumour disappear (< 0.01cm3) first but grow back in later weeks
up to the end of the experiment. These mice cannot be considered as cured
ones but the intermittent missing values are truncated as 0.01cm3. We are
therefore motivated by this dataset to build longitudinal models for repeated
measurements of the tumour volume, survival models for time-to-death or
sacrifice of the mice, and cure models for the cured mice, simultaneously.
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2.2 Longitudinal data sub-model
Consider in general the anti-tumour activity of S agents. Suppose that there
are n + 1 pre-specified follow-up times t0 < t1 < · · · < tn for each of the m
subjects/mice. Let Yi(tj) be the tumour volume of the ith mouse measured
at the time tj (j = 0, 1, · · · , n). To make the data normally distributed,
we assume that a log scale has been introduced to Yi(tj). Denote x
(s)
i (t)
(s = 1, · · · , r) as the cumulative dose of the sth agent (or interactions of two
agents) administered to the ith mouse until the time t.
The responses Yi(tj) (j = 1, ..., ni and i = 1, ...,m) may be modelled by a
linear mixed model [22]
Yi(tj) = ψ0 + ψ1tj + ψ2t
2
j +X i(tj)β + ui0 + ui1tj + εij, (1)
where the random effect ui = (ui0, ui1)
′ follow a normal distributionN2(0,Σu),
ψ = (ψ0, ψ1, ψ2) and β = (β0, ..., βr)
′ are unknown parameter vectors,X i(tj) =
(x
(1)
i (tj), ..., x
(r)
i (tj)), and random errors εij are independent and normally
distributed with E(εij) = 0 and Var(εij) = σ
2
ε .
Here we consider such a simple quadratic baseline tumor growth model
ψ0 + ψ1tj + ψ2t
2
j , because the plot of log-tumor size against time shows a
quadratic trajectory, see Figure 1 of the Supplementary Web Materials. For
simplicity we consider a simple linear random effects model ui0 + ui1t to
capture the within-subject correlation between the repeated measures of the
tumour volume. Note that the models can be extended to more complicated
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tumor growth models [23] involving more random effects.
As pointed out by [1], in the xenograft experiments the tumour born by an
immunosuppressants mouse in the control group is expected to grow over
the follow-up period. Ignoring this fact can lead to misleading inferences,
for example, resulting in underestimates of treatment effects [1]. In order to
reflect this fact in the model, ψ is assumed to be such that,
Condition 1: The quadratic polynomial in time
ψ0 + ψ1t+ ψ2t
2 (2)
is an increasing function for t > 0. 
As long as ψ1 + 2ψ2t > 0 where t > 0, Condition 1 above holds. A special
case is a straight line with ψ2 = 0 and ψ1 > 0. We denote Ψ = {ψ :
such that ψ1 + 2ψ2t > 0}. In other words, Ψ is the collection of all possible
values of ψ1 and ψ2 such that the quadratic polynomial in (2) is an increasing
function.
2.3 Proportional hazard and cure sub-models
Note that we cannot justify whether a mouse is really cured or not, since
when tumor size is less than 0.01 cm3 it can not be measured and we do
not know whether the tumor really disappear or not. It happened in several
mice that the tumor size became smaller than 0.01 and reoccur later on. In
practice, the experiment researchers usually assume that if the tumor size is
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less than 0.01 at week 12, the end of the experiment, then the tumor will
never reappear, i.e. a mouse is ‘cured’ eventually.
Let ξi = 0 denote the ith mouse ‘cured’ by agents and ξi = 1 be not ‘cured’.
Assume pi = Pr(ξi = 1), the probability of incidence that the event, death
caused by the tumour problem or toxicity of agents, occurs by the end of
the experiment. Obviously, a cured mouse does not experience the death
or sacrifice in the experiment period. Conversely, a mouse who died or was
sacrificed during the experiment period must have the incidence ξi = 1. In
addition, we may not know whether a mouse is cured or not, if the tumor is
larger than 0.01 by the end of the experiment.
Therefore it is clear that the binary incidence indicator ξ will have three
possibilities: (a) when the censoring occurs (δi = 0), the incidence indicator
ξi will be unobserved if the tumor size at the censoring time, i.e., week 12, is
larger than 0.01; (b) when the censoring occurs (δi = 0) and the tumor size
at the censoring time is not more than 0.01 at week 12. That is, the tumor
almost disappears by the end of the experiment, so that it can be treated as
ξi = 0 (cured); (c) the censoring does not occur, i.e., the failure indicator is
δi = 1, so that ξi = 1 (not cured).
Let Ti be the time to death for the ith individual, defined only for those
with ξi = 1, with the hazard function h(t|ξi = 1) and the survival function
S(t|ξi = 1). If a mouse survives longer than the experiment period, the
survival time of the mouse is censored as the mouse is either cured or has no
enough follow-up times. In other words, we actually observe T˜i = min(Ti, Ci)
10
and δi = I(Ti ≤ Ci) where Ci is the censoring time and δi is the relative failure
indicator.
The marginal survival function of Ti therefore is given by
Si(t) = Pr(Ti ≥ t)
= Pr(Ti ≥ t|ξi = 0)Pr(ξi = 0) + Pr(Ti ≥ t|ξi = 1)Pr(ξi = 1)
= 1− pi + piS(t|ξi = 1) (3)
for t <∞. Note that Si(t)→ (1− pi) as t→∞, implying that the marginal
survival function Si(t) tends to the cure probability (1 − pi) for large t. As
long as the incidence probability pi and the conditional survival function
S(t|ξi = 1), or the conditional hazard function h(t|ξi = 1), are obtained, the
marginal survival function Si(t) can be formed using (4). In what follows we
discuss how to model h(t|ξi = 1) and pi in terms of covariates of interest.
For simplicity, we assume the censoring mechanism is noninformative and is
independent of the longitudinal response Y .
Farewell [25] proposed to use the following logistic regression model
Pr(ξi = 1|zi) = exp(z
′
iλ)
1 + exp(z′iλ)
to model the incidence probability pi, where zi and λ are covariates and
parameters, respectively. He also suggested a parametric survival model for
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S(t|ξ = 1). Sy and Taylor [16] proposed the proportional hazard cure model
hi(t|ξi = 1,wi) = h0(t|ξi = 1) exp(w′iα),
where wi and α are covariates and parameters, respectively, and h0(t|ξi = 1)
is the conditional baseline hazard function. This model is not designed for
cases where longitudinal data exist.
The models above, however, take no account of the likely relation among
the incidence probability, the conditional hazard function and the tumour
volume Y . As a result, the separate use of those models may lead to biased
statistical inferences. Instead, we propose to use the random effects ui in the
longitudinal model (1), to link the longitudinal and survival-cure models. In
other words, we use the following logistic regression model
Pr(ξi = 1|zi,ui) = exp(z
′
iλ+ pi
′
2ui)
1 + exp(z′iλ+ pi
′
2ui)
(4)
to model the incidence probability, and use the following proportional hazard
frailty model (see [7])
hi(t|ξi = 1,ui,w) = h0(t|ξi = 1) exp(w′i(t)α+ pi11(ui0 + ui1t) + pi12ui0 + pi13ui1) (5)
to model the conditional hazard function, where pi1 = (pi11, pi12, pi13) in (5)
and pi2 = (pi21, pi22)
′ in (4) are unknown link parameters. If the estimators of
pi1 and pi2 are statistically significant, we conclude that the joint modelling of
the longitudinal and survival-cure data is necessary. Otherwise, the separate
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modelling strategy may be preferred.
Note that the incidence probability in (4) considered here is the probability
that the incidence event eventually occurs. Therefore it does not depend on
time. In our model the incidence probability depends on zi (e.g. treatments)
and ui (the tumor characteristics: baseline effect ui0 and rate effect ui1). We
may consider that the incidence probability depends on time. This may be
done by using a competing risk model or a Markov transition model to model
the hazard rates for death event and cure event. But in the study the cure
event time was not observed exactly, and hence here we only consider the
simple model (4). Although a mouse whose tumor size is less than 0.01 at
week 12 was considered as cured, it is not clear when exactly the mouse’s
tumor disappears due to the constraint of the tumor size reading machine.
2.4 Complete log-likelihood function
Given random effect ui, we assume the longitudinal data and survival-cure
data are independent. It is noted that the incidence ξi may be observable
or unobservable, depending on whether or not the censoring occurs. De-
fine ξ = {ξo, ξm} as the set of all the incidences ξi’s, where ξo and ξm
are the collections of the observable and unobservable incidences, respec-
tively. The observed data are then D = {(Yi, Ti, δi, Xi, wi, zi) : i = 1, ...,m}
and ξo. Then the complete log-likelihood function of the parameters Θ =
(β,α,λ, σ2ε ,Σ
2
u,ψ,pi1,pi2, h0) and the unobservable data (u, ξ
m), apart from
13
a constant, can be written as
`(Θ,u, ξm|D, ξo)
= − N
2
log σ2ε −
1
2σ2ε
m∑
i=1
ni∑
j=1
(Yi(tj)− ψ0 − ψ1tj − ψ2t2j −X iβ − ui0 − ui1tj)2
+
m∑
i=1
{
δiξi
(
log h0(T˜i|ξi = 1) +w′i(T˜i)α+ pi11(ui0 + ui1T˜i) + pi12ui0 + pi13ui1
)
− ξi
∫ T˜i
0
h0(t|ξi = 1) exp(w′i(t)α+ pi11(ui0 + ui1t) + pi12ui0 + pi13ui1)dt
}
− m
2
log |Σu|
+
m∑
i=1
{
ξi(z
′
iλ+ pi2ui)− log(1 + exp(z′iλ+ pi2ui))
}
− 1
2
u′iΣ
−1
u ui. (6)
Note that for the above log-likelihood function, the domain for ψ is Ψ de-
fined in Condition 1, the intrinsic condition. Therefore, under the intrinsic
condition, the log-likelihood will be −∞, if the ψ /∈ Ψ; the log-likelihood is
given by the above formula (6) if ψ ∈ Ψ.
For the baseline hazard function h0(t|ξi = 1), we assume it is a piecewise
constant function as well, that is,
h0(t|ξi = 1) = h0k, for tk−1 ≤ t < tk (k = 1, · · · , nh), (7)
where h0 = (h01, · · · , h0nh)′ are unknown parameters and nh is not greater
than n.
In our study w′i(t) is chosen as the cumulative dose level until time t and
it is thus a piecewise constant. Therefore the evaluation for the integration
in (6) is straightforward. Even if there is a dependence on t2 in the definite
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integration of (6), it can still be evaluated numerically by using the command
‘integrate’ in the R package. Therefore this will not limit the applicability of
our model.
3 Bayesian Inference
We propose to use a Bayesian approach to make statistical inferences for
the joint models (1), (4) and (5) to avoid the analytical intractable inte-
gral problem involved in the marginalized log-likelihood function. Markov
chain Monte Carlo (MCMC) is applied in our implementation. Rather than
integrating out the random effects ui and the missing values ξ
m from (6),
we sample u and ξm, as well as other parameters, from their corresponding
conditional posterior distributions.
We specify independent normal priors for the parameters β, α and λ, of
which all are assumed to have very large variances. We also specify inverse
Gamma and inverse Wishart priors for the random errors variance σ2ε and
random effects variance Σu, respectively. We choose a Gamma prior for each
h0j (j = 1, 2, ..., n), so that a conjugate posterior distribution for h0j is easy
to obtain. We assume a normal distribution, N(τ, ς), as the prior for each
component of the link parameters pi1 and pi2.
We propose to use the DIC value to select the most appropriate model. The
DIC value consists of two terms, one for goodness-of-fit measured by the
deviance evaluated at the posterior mean of parameters, and the other ac-
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counting for a penalty defined by twice of the effective number of parameters.
The latter is defined by the mean deviance minus the deviance evaluated at
the posterior mean. Under the model assumption with missing data, the DIC
is defined by
DIC = −4EΘ,u,ξm [`(Θ,u, ξm|D, ξo)|D, ξo)] + 2Eu,ξm [`(Θ˜,u, ξm|D, ξo)|D, ξo)]
where Θ˜ = E[Θ|D, U, ξm, ξo]. See [27] and [28] for more details.
4 Real data analysis
Following the notation in Section 2, we denote ni as the number of repeated
measurements for the ith mouse (ni ≤ 12). Let x(1)i (t) be the cumulative dose
of TMZ and x
(2)
i (t) be the cumulative dose of CPT-11, which are received
by the ith mouse till week t (t = 1, ..., ni, i = 1, ..., 51). To account for the
synergism of the two drugs, following [1] we take x
(3)
i (t) =
√
x
(1)
i (t)x
(2)
i (t) as
the interaction term. Let X i(t) = (x
(1)
i (t), x
(2)
i (t), x
(3)
i (t))
′. The longitudinal
sub-model in (1) is then used to model the activity of the TMZ combined
with CPT-11 against Rh18 tumour growth for the ith mouse in the xenograft
experiments. In our data analysis studies, we rescale time points as tj = tj/10
and the dose level of TMZ divided by 100.
Among the 51 mice, in total 25 mice died of toxicity or were sacrificed as
the tumour volumes were quadrupled. On the other hand, 14 mice were
considered to be cured by the end of the experiment, as they survived 12
16
months and have tumor size smaller than 0.01. The remaining 12 mice were
not cured by the end of the experiment but survived longer than 12 week,
so that their true lifetimes and cure incidence indicators are not observable.
We then use the survival model (5) to model the conditional hazard function
hi(t|ξi = 1,wi(t),ui), where wi(t) = X i(t−) is the value of X i right before
the time point t. The baseline hazard rate h0(t|ξi = 1) is assumed to be a
piecewise constant function
h0(t|ξi = 1) = h0j, tj−1 ≤ t < tj, (j = 1, ·, nh)
where we choose nh = 4 because in the 12-week period of experiment the
treatments are given to mice as a cycle of every three weeks (see Table 1 in
the supplementary file).
We also use the model (4) to model the incidence probability Pr(ξi =
1|zi,ui), where zi = (z(1)i , z(2)i , z(3)i , 1)′ in which z(1)i and z(2)i are the average
weekly-dose levels of TMZ and CPT-11 for subject i, respectively, and z
(3)
i
is the associated interaction term. Note that we use the weekly-average dose
levels z
(s)
i rather than the cumulative dose x
(s)
i (t) (s = 1, 2, 3) as the covari-
ates for modeling of the incidence probability Pr(ξi = 1|zi,ui). The reason
is that our aim is to model how the incidence probability Pr(ξi = 1|zi,ui)
depends on treatments rather than time or time-related variables such as the
cumulative dose x
(s)
i (t). It is noted that different weekly-average dose level is
taken as a different treatment here. Of course, it may be of interests to see
how the incidence probability is related to the tumor volume that changes
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over time. In this case, the model for the incidence probability is a dynamic
model and the latent Markov transition model proposed by [29] may be a
key to resolve the issue. We leave this as future work.
The parameters of interest in the survival-cure models are the fixed effects
parameters α = (α1, α2, α3)
′, λ = (λ1, λ2, λ3, λ4)′ and the link parameters pi1
and pi2.
Following [21], the prior for each element of β, α and λ is chosen to be
N(0, 10000). The priors for σ−2 and each element of h0 are all chosen to be
Gamma(0.001, 0.001). The priors for Σu is taken to be the inverse Wishart
distribution with parameters (4, I2). For each element of the link parameters
pi1, pi2, a non-informative normal prior N(0, 100) is applied.
To see if the model links are really necessary, we consider the following four
possible link scenarios.
Case 1: longitudinal and survival-cure models are linked by pi1 and pi2.
Case 2: longitudinal and survival models are linked by pi1 (i.e. pi2 = 0).
Case 3: longitudinal and cure models are linked by pi2 (i.e. pi1 = 0).
Case 4: neither of these models are linked (i.e. pi1 = 0,pi2 = 0).
In Table 1 we summarize the posterior means and 95% credit intervals of the
parameters in the models for each case above. We also provide the relative
DIC values for all the four possible scenarios. In each case, we uses 10,000
iterations of MCMC sampling chains following a 5,000-iteration ‘burn-in’
period.
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[Table 1 about here.]
From Table 1, it turns out that the smallest DIC value is achieved by the
model that links all the three sub-models, implying that the joint modelling
may be necessary. The TMZ, the CPT-11 treatments and their interaction
all have significant negative effects on the tumour growth, implying the treat-
ments work in reducing the tumour growth. For the incidence model, we can
see that the two treatments and their interaction have no significant effects
on the incidence probability. The only significant estimate is for the inter-
cept parameter λ4, which is about 3.101, leading to the incidence probability
being 96% in the absence of treatments. In other words, without treatments
the tumour-beard mice have only 4% chances to be cured. The parameters
λ2 = −2.799 and λ3 = −1.884 are not significant, but their large negative
values also suggest CPT-11 and the interaction of TMZ and CPT-11 may
have effects on the incidence probability, i.e. treatments will increase the
probability of cure. For the survival model, the CPT-11 has a significant
positive effect on the survival time, but and TMZ-11 and the interaction of
the two treatments are not significant.
For the model that links all the three sub-models, the estimate for the link
parameter pi11 = 0.141 is significant. This implies that individual tumor
departure from the mean tumor size is a significant risk factor for survivals.
The link parameter pi11 is positive, showing that the bigger the Rh18 tumour
volume departure from the mean tumor size the higher the hazard rate of
death. The link parameter pi12, pi13 are not significant, showing that the
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individual departures from the intercept and from the slope do not have
effects on survival. For the link parameter pi2 = (pi21, pi22), the estimate for
pi22 is significant, but the estimate for pi21 is not significant. This implies
that the gradient ui1 (the rate of individual tumor growth) is a significant
risk factor for the incidence probability. The higher the individual tumor
growth rate, the lower the cure probability. Note that, for the full model
(case 1), the random slope is the only significant predictor of cure.
When only having the link for the longitudinal and survival sub-models (case
2 in Table 1), all the link parameters of pi1 are not significant, which implies
that the tumor growth does not have significant effects on survival. This
conflicts with reality. In addition, without having the second link parameter
pi2, the parameter vector λ2 becomes significant (cases 2 and 4). The main
reason for this is that the random effects are not considered in cases 2 and
4, which distorts the estimate of the fixed-effect parameter vector λ.
When only having the link parameter pi2 (case 3 in Table 1), the link pa-
rameter pi22 is also significant. Although most results in case 3 are similar to
those in case 1, without having the first link parameter (case 3) has a smaller
estimate for |α2| = 0.128 than |α2| = 0.257 in case 1. Without the first link
parameter, we may underestimate the effects of the treatment agent CPT-11,
which is the only significant risk factor for survivals. For this reason and the
DIC values, we suggest that case 1, the full model, is more suitable for the
data.
We also considered the models without using the intrinsic growth constraint.
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The results for the full model and separated models are provided in the
supplementary materials. Basically the results of having the intrinsic growth
and without having the intrinsic growth are consistent. The main difference
is as follows. Without having the constraint, the baseline tumor volumes (i.e.
no treatment) is estimated by φ2t
2 + φ1t+ φ0, with φ2 = 5.598, φ1 = −3.624
and φ0 = −0.187. This implies that without treatment, the tumor will
decrease approximately before time 0.3 (week 3 as we use week divided by
10 for the new time scale), and then increase after that. However, this is not
correct in practice, since the tumor will surely increase if no treatments are
received. With having the constraint, the baseline tumor volume is estimated
as 3.869t2 + 0.158t− 0.561, an increasing function of time t.
5 Simulation studies
We mimic the real data in Section 4 in the following simulation studies. The
covariates X i(t), wi(t) and zi are the same as that in the real data study.
In other words, we have three covariates in the simulation: two treatments
TMZ and CPT-11, and their interaction. These covariates are included in
both the longitudinal and survival models. We also choose two dose levels
for the TMZ 42 mg/kg and the CPT-11 0.61 mg/kg and then consider eight
groups of treatments as that in data analysis. The sample size is m = 51
and the number of samples in each group is the same as that in the real
data study. The independent random effects ui are assumed to follow Nor-
mal distribution N2(0,Σu), the independent random errors εij follow Normal
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distribution N(0, σ2ε), and ui and εij are mutually independent.
Given the random effects ui and covariates zi, the incidence event ξi is gen-
erated from the model (4).
For those subjects with incidence indicator ξi = 1, on the other hand, the
survival model (5) is used to generate the survival outcomes Ti. To mimic
the data, the baseline hazard rate h0(t|ξi = 1) is assumed to be a piecewise
constant function
h0(t|ξi = 1) = h0j, tj−1 ≤ t < tj, (j = 1, · · · , n)
and h01 = 1.6, h02 = 3.0, h03 = 9.8, h04 = 16.7, which are similar to the esti-
mated values in the real data analysis. It is assumed that the baseline hazard
has an increasing jump because the hazard rate increases in the absence of
treatments.
Our data are generated from the full model, with linking parameters pi11 =
0.6, pi12 = 0.7, pi13 = 0.0, pi21 = 0 and pi22 = 1.22.
We compare the simulation results for two models, the model with the as-
sociation (pi1 6= 0 and pi2 6= 0) and the model without the association
(pi1 = 0,pi2 = 0). We simulate 100 data sets and calculate the sample
mean and the sample standard deviation for each parameter estimator. For
each data set, we draw 5,000 random samples from the posterior distributions
following a 5,000-iteration ‘burn-in’ period in order to estimate the param-
eters. Table 2 provides the parameter estimators, standard deviations and
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coverage probability of credible interval.
From Table 2, we can see that the joint models and the separated mod-
elling give similar parameter estimates for the longitudinal sub-model. When
the latent association of longitudinal and survival-cure data does exist, i.e.,
pi11 6= 0, pi12 6= 0 and pi22 6= 0, the proposed joint modelling approach per-
forms well. For example, the link parameter estimators of pi11, pi12 and pi22
are statistically significant and very close to the true parameter values, which
correctly identifies that the joint models are really necessary. On the con-
trary, the separated modelling approach that ignores the existing inherent
association gives estimates with larger bias for most of the parameter esti-
mation, except for α2 and λ2. In addition, the separate model has lower
coverage probability for α1 and β3. The two models give similar coverage
probabilities for all other parameters. Overall, statistical inferences for the
survival models using the joint modelling approach are more sensible and
reliable than those using the separate modelling method.
[Table 2 about here.]
6 Discussion
In this paper we propose a joint modelling approach to account for the likely
inherent association for longitudinal data and survival-cure outcomes. We
propose to use common random effects to connect the different models. The
approach is then used to analyze a real data set arising from tumour xenograft
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experiments. Bayesian inferences are obtained using an MCMC approach,
showing the parameter estimators from the posteriors are robust against the
priors of the link parameters. Our conclusion on the data analysis is mostly
consistent with [24] but the inherent association of different types of data is
taken into account so that more information is discovered. Simulation studies
show that the proposed joint modelling approach produces very satisfactory
parameter estimators.
Some further research needs to be studied when each mouse has multiple
tumours. [21] described an example of preclinical studies evaluating the
anti-tumour effects of exemestane and tamoxifen for postmenopausal breast
cancer, in which each mouse received subcutaneous injections at two sites
and developed four tumours in the process. It is anticipated that multivariate
longitudinal responses and multi-dimensional random effects will be involved
and additional correlation between tumours for the same mice should be
accounted for. We will report this in a follow-up paper.
In our study, the cure probability is just the probability that a mouse is
cured or not, eventually. It does not depend on time, which is a limitation
of our work. In other studies, it may also be interesting to consider that the
cure probability depends on time, if the cure times are available. A Markov
transition model might be employed to deal with such problems.
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Figure 1: Observed tumor volumes for the eight treatment groups for 8
groups
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Table 1: Posterior mean (95% credible interval) of the parameters and the
DIC values. Parameter β corresponds to the covariate effects for the tumor
sizes; parameter α correspond to the covariate effects on the survival time;
parameter λ correspond to the covariate effects on the incidence probability.
Par. Case 1 Case 2 Case 3 Case 4
DIC 477.1 518.3 530.7 555.4
Longitudinal
submodel ψ0 -0.561 -0.442 -0.227 -0.484
(-0.996, -0.232) (-0.755, -0.199) (-0.635,0.202) (-0.765, -0.164)
ψ1 0.158 0.286 0.242 0.472
(0.005, 0.696) (0.008, 0.829) (0.007,0.690 ) (0.014, 1.241)
ψ2 3.869 4.251 4.402 4.243
(3.401, 4.307) (3.655,4.946) (3.804, 5.038) (3.560, 4.901)
Longitudinal
TMZ β1 -0.289 -0.272 -0.248 -0.237
(-0.404, -0.177) (-0.399, -0.130) (-0.347, -0.136) (-0.401, -0.112)
CPT-11 β2 -0.253 -0.236 -0.231 -0.256
(-0.297, -0.206) (-0.280, -0.181) (-0.279,-0.194) (-0.318, -0.189)
Interaction β3 -0.070 -0.069 -0.128 -0.052
(-0.130, -0.016) (-0.112, -0.012) (-0.245,-0.052) (-0.144, -0.029)
Survival
TMZ α1 -0.142 -0.056 -0.073 -0.056
(-0.461, 0.198) (-0.297, 0.167) (-0.285,0.126) (-0.267, 0.146)
CPT-11 α2 -0.257 -0.119 -0.128 -0.118
(-0.453, -0.092) (-0.218,-0.017) (-0.222,-0.039) (-0.210,-0.031 )
Interaction α3 0.509 0.380 0.232 0.402
(-0.322,1.380) (-0.090, 0.740) (-0.299,0.665) (-0.010,0.741)
Cure
TMZ λ1 -0.368 -0.241 0.092 0.018
(-2.797, 2.487) (-1.581,2.176) (-2.316,2.769) (-1.794,2.196)
CPT-11 λ2 -2.799 -2,289 -2.455 -2.301
(-5.513, 0.667) (-4.138, -0.617) (-5.029,-0.068) (-4.263,-0.773)
Interaction λ3 -1.884 -2.025 -2.022 -1.910
(-5.234 1.696) (-4.427, 0.266) (-5.184,1.243) (-4.663, 0.577)
Constant λ4 3.101 2.813 3.404 2.942
(0.399, 5.395) (0.720, 4.007) (1.203,6.169) (1.051, 5.036 )
Links between survival and longitudinal
ui0 + ui1t pi11 0.141 0.035 0 0
(0.033, 0.295) (-0.177, 0.378) – –
ui0 pi12 0.161 0.0152 0 0
(-0.599, 0.717) (-0.258, 0.344) – –
ui1 pi13 0.092 0.003 0 0
(-0.387, 0.311) (-0.235, 0.202) – –
Links between curel and longitudinal
ui0 pi21 -0.713 0 -0.164 0
(-4.672, 2.044) – (-2.801, 1.684) –
ui1 pi22 2.006 0 1.128 0
(0.433, 5.676) – (0.372, 2.685) –
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Table 2: Simulation results for the case that there is a latent association, i.e.,
pi1 6= 0 and pi2 6= 0. The sample size m=51.
Par. True Separate modelling Joint modelling
Estimates St.D. Coverage prob Estimates St.D. Coverage
ψ0 -0.40 -0.395 0.038 0.95 -0.382 0.040 0.96
ψ1 0.80 0.835 0.244 0.94 0.823 0.279 0.95
ψ2 3.60 3.587 0.170 0.95 3.604 0.168 0.96
β1 -0.30 -0.309 0.018 0.96 -0.308 0.016 0.93
β2 -0.27 -0.273 0.010 0.90 -0.273 0.010 0.90
β3 -0.01 -0.015 0.012 0.85 -0.008 0.012 0.90
α1 0 -0.184 0.140 0.88 -0.171 0.139 0.90
α2 -0.22 -0.220 0.054 0.96 -0.236 0.077 0.96
α3 0 0.135 0.122 0.93 0.116 0.155 0.94
λ1 0 0.759 0.658 0.90 0.701 0.772 0.93
λ2 0 -0.164 0.531 0.97 -0.184 0.552 0.97
λ3 0 -0.070 0.362 0.95 -0.060 0.334 0.97
λ4 3.35 4.154 0.881 0.91 4.015 0.960 0.91
pi11 0.6 - - - 0.544 0.206 0.95
pi12 0.7 - - - 0.688 0.201 0.96
pi13 0.0 - - - 0.056 0.125 0.94
pi21 0.0 - - - -0.055 0.197 0.96
pi22 1.22 - - - 1.186 0.173 0.96
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